Drug | Age | ||
---|---|---|---|
7–14 Days | 28–35 Days1-a | 45–52 Days | |
GABA (I max)b,c,d | 476 ± 65 pA | 842 ± 54 pA | 893 ± 160 pA |
GABA (EC50) | 40 ± 8 μM | 46 ± 10 μM | 31 ± 10 μM |
Diazepam (EC50)1-e | 648 nM | 158 ± 13 nM | 24 ± 7 nM |
Zolpidem (EC50) | 75 ± 13 nM | 34 ± 17 nM | |
Furosemide (IC50)1-d | 492 ± 79 μM | Biphasic | 1605 ± 199 mM |
Zinc (IC50)a,d,e | 40 ± 5 μM | 28 ± 11 μM | 103 ± 19 μM |
Loreclezole (% sensitive cells)1-f | 30 | 50 | 70 |
↵1-a These data were from a previous publication by the authors using the same techniques used in the current experiments.
1-b P < .05, one-way ANOVA.
1-c P < .05, Newman-Keuls multiple-comparison test between columns 7–14 days and 28–35 days.
↵1-d P < .05 Newman-Keuls multiple-comparison test between columns 7–14 days and 45–52 days. Grouped ttest was used when only two cells of data were compared, for drugs diazepam, zolpidem, and furosemide.
↵1-e P < .05 Newman-Keuls multiple-comparison test between columns 28–35 days and 45–52 days.
↵1-f P < .05, χ2 test comparison between columns 7–14 days and 45–52 days.